{"id":210071,"name":"UCB, INC.","slug":"ucb-inc","state":"GA","country":"United States of America","description":"Biopharmaceutical company dealing in severe diseases in immunology and neurology.","totalSpending":1100000,"filings":20,"yearlySpending":[{"year":2021,"income":140000},{"year":2022,"income":240000},{"year":2023,"income":260000},{"year":2024,"income":220000},{"year":2025,"income":240000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"TAX","display":"Taxation/Internal Revenue Code"}],"firms":["VENN STRATEGIES"],"lobbyists":["STEPHANIE SILVERMAN","ERIK OLSON","ELIZABETH LEE","MICHAEL SPIRA","GRANT COUCH","MELISSA FRANCIS (FORMERLY BONICELLI)","JONATHAN PYATT","SAMUEL GOODSTEIN","JUSTIN LIVESEY"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Matters related to innovation in, and patient access to, biopharmaceutical therapies.","Matters related to innovation in, and patient access to, biopharmaceutical therapies.","Issues regarding FDA PDUFA procedures in COVID.","Issues regarding FDA PDUFA procedures in COVID.","Policies related to biopharmaceutical access and innovation."]}